Lupin on Wednesday said it has received approval from the USFDA for Formoterol Fumarate Inhalation Solution, used in treating symptoms of chronic obstructive pulmonary disease.
The company has received approval from the US Food and Drug Administration (USFDA) for the product which is a generic version of Mylan Specialty’s Perforomist Inhalation Solution, the Mumbai-based drug maker said in a statement.
As per IQVIA MAT June 2022 data, the medication had annual sales of around USD 282 million in the US market.
Shares of Lupin ended 2.55 per cent down at Rs 677.65 apiece on the BSE on Wednesday.
(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)
Members can access their health plan benefits through mybenefits.nationsbenefits.com. The portal allows users to check…
A new lawsuit claims T-Mobile promised $200 gift cards for new lines but did not…
The IRS allows eligible families to claim a Child Tax Credit of up to $2,000…
Lloyds Bank customers faced a major app problem after a technical glitch showed other people’s…
Activating your JetBlue Mastercard online is quick and simple. Visit the official activation website, enter…
Activating a US Bank ReliaCard online is quick and simple. Visit the activation website, enter…